Cargando…
Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients wit...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292964/ https://www.ncbi.nlm.nih.gov/pubmed/34307125 http://dx.doi.org/10.3389/fonc.2021.641522 |
_version_ | 1783724929612513280 |
---|---|
author | Zeng, Zhi Lu, Qiliang Liu, Yang Zhao, Junjun Zhang, Qian Hu, Linjun Shi, Zhan Tu, Yifeng Xiao, Zunqiang Xu, Qiuran Huang, Dongsheng |
author_facet | Zeng, Zhi Lu, Qiliang Liu, Yang Zhao, Junjun Zhang, Qian Hu, Linjun Shi, Zhan Tu, Yifeng Xiao, Zunqiang Xu, Qiuran Huang, Dongsheng |
author_sort | Zeng, Zhi |
collection | PubMed |
description | Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients with advanced HCC, its efficacy is limited by drug resistance in some patients. In HCC, this resistance is attributed to multiple complex mechanisms. Previous clinical data has shown that HIFs expression is a predictor of poor prognosis, with further evidence demonstrating that a combination of sorafenib and HIFs-targeted therapy or HIFs inhibitors can overcome HCC sorafenib resistance. Here, we describe the molecular mechanism underlying sorafenib resistance in HCC patients, and highlight the impact of hypoxia microenvironment on sorafenib resistance. |
format | Online Article Text |
id | pubmed-8292964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82929642021-07-22 Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma Zeng, Zhi Lu, Qiliang Liu, Yang Zhao, Junjun Zhang, Qian Hu, Linjun Shi, Zhan Tu, Yifeng Xiao, Zunqiang Xu, Qiuran Huang, Dongsheng Front Oncol Oncology Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients with advanced HCC, its efficacy is limited by drug resistance in some patients. In HCC, this resistance is attributed to multiple complex mechanisms. Previous clinical data has shown that HIFs expression is a predictor of poor prognosis, with further evidence demonstrating that a combination of sorafenib and HIFs-targeted therapy or HIFs inhibitors can overcome HCC sorafenib resistance. Here, we describe the molecular mechanism underlying sorafenib resistance in HCC patients, and highlight the impact of hypoxia microenvironment on sorafenib resistance. Frontiers Media S.A. 2021-07-07 /pmc/articles/PMC8292964/ /pubmed/34307125 http://dx.doi.org/10.3389/fonc.2021.641522 Text en Copyright © 2021 Zeng, Lu, Liu, Zhao, Zhang, Hu, Shi, Tu, Xiao, Xu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zeng, Zhi Lu, Qiliang Liu, Yang Zhao, Junjun Zhang, Qian Hu, Linjun Shi, Zhan Tu, Yifeng Xiao, Zunqiang Xu, Qiuran Huang, Dongsheng Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma |
title | Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma |
title_full | Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma |
title_fullStr | Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma |
title_full_unstemmed | Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma |
title_short | Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma |
title_sort | effect of the hypoxia inducible factor on sorafenib resistance of hepatocellular carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292964/ https://www.ncbi.nlm.nih.gov/pubmed/34307125 http://dx.doi.org/10.3389/fonc.2021.641522 |
work_keys_str_mv | AT zengzhi effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT luqiliang effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT liuyang effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT zhaojunjun effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT zhangqian effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT hulinjun effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT shizhan effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT tuyifeng effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT xiaozunqiang effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT xuqiuran effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma AT huangdongsheng effectofthehypoxiainduciblefactoronsorafenibresistanceofhepatocellularcarcinoma |